**FORUM:** General Assembly 3- Social, Humanitarian and Cultural

**QUESTION OF:** Establishing protocols to balance the Intellectual Property rights of pharmaceutical companies with efforts to facilitate access to medicines.

**MAIN SUBMITTER:** The Netherlands

**CO-SUBMITTER:**

THE GENERAL ASSEMBLY,

*Convinced* that the general assembly’s policy “The Resolution on Access to Medicines in the Context of the Right of Everyone to the Enjoyment of the Highest Attainable Standard of Physical and Mental Health” will be successful in achieving its aims,

*Congratulating* Sweden for founding a non-profit, governmentally run establishment that could sell pharmaceuticals cheaper than before, thanks to governmental funding. This resulted in greater accessibility for the entire population,

*Aware of* the fact that this issue has only been relevant for a short period of time, since advanced medicine has only been available in recent history,

*Recognizes* the importance of producing drugs at a lower price to ensure the equal availability to all in habitants,

*Emphasizes* that all citizens of the world are entitled to access orphan drugs, because according to the Universal declaration of Human Rights article 25;

1. Proposes non-profit governmentally run monopolies that can balance funding that would come to affect 2025, thereby assuring greater accessibility to orphan drugs;
2. Suggests establishing a similar solution to the Swedish establishment Apoteket AB since it has been able to increase accessibility to treatments and medicines for the Swedish population;
3. Encourages the creation of pharmaceutical unions between countries to broaden the orphan drug market and thereby decreasing the production costs;
4. Invites all UN nations to introduce max prices on pharmaceuticals, thereby making treatments more affordable for underprivileged citizens;
5. Further Encourages all member states to establish a governmental health care system, where a minimum health care teatment is ensured by law;
6. Supports imposing innovation grants to increase orphan drug research motivation resulting in increased research and production within this area.